Distribuzione geografica
Continente #
NA - Nord America 1469
EU - Europa 1141
AS - Asia 125
SA - Sud America 4
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 2747
Nazione #
US - Stati Uniti d'America 1463
IE - Irlanda 894
CN - Cina 112
IT - Italia 71
DE - Germania 48
FI - Finlandia 37
SE - Svezia 17
BE - Belgio 13
AT - Austria 10
GB - Regno Unito 10
UA - Ucraina 10
MK - Macedonia 9
RU - Federazione Russa 8
FR - Francia 7
CA - Canada 6
IN - India 5
EU - Europa 3
RO - Romania 3
TR - Turchia 3
AR - Argentina 2
EG - Egitto 2
PH - Filippine 2
AU - Australia 1
BG - Bulgaria 1
BR - Brasile 1
CO - Colombia 1
HK - Hong Kong 1
IR - Iran 1
KZ - Kazakistan 1
MU - Mauritius 1
NL - Olanda 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RS - Serbia 1
Totale 2747
Città #
Dublin 893
Chandler 536
Princeton 140
Lawrence 135
Medford 129
Wilmington 110
Helsinki 31
Pavia 29
Beijing 28
Norwalk 27
Jacksonville 24
Nanjing 21
Fairfield 17
Woodbridge 16
Redwood City 14
Ann Arbor 13
Brussels 13
Hebei 11
Milan 10
Nanchang 9
Vienna 9
Falls Church 7
Hangzhou 7
Changsha 6
Toronto 6
Dearborn 5
Jiaxing 5
San Francisco 5
Shenyang 5
New Delhi 4
Skopje 4
Berlin 3
Bologna 3
Chengdu 3
Las Vegas 3
Monmouth Junction 3
Tianjin 3
Arcore 2
Ashburn 2
Bergamo 2
Biassono 2
Borås 2
Buenos Aires 2
Chicago 2
Desio 2
Hefei 2
Houston 2
Jinan 2
Manila 2
Redmond 2
Scuola 2
Alba 1
Almaty 1
Ankara 1
Arnesano 1
Belfort 1
Belgrade 1
Boardman 1
Cairo 1
Cambridge 1
Corridonia 1
Des Moines 1
Duncan 1
Dundee 1
Florence 1
Frankfurt am Main 1
Fremont 1
Fuzhou 1
Galati 1
Henderson 1
Kashan 1
London 1
Melbourne 1
Messina 1
Osimo 1
Paris 1
Pinehaven 1
Plovdiv 1
Prilep 1
Rockville 1
Rome 1
Sacramento 1
Shanghai 1
Southend 1
Turin 1
Velikiy Novgorod 1
Verona 1
Vidin 1
Wuhan 1
Zhengzhou 1
Totale 2354
Nome #
Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice 69
Drug eluting stents are superior to bare metal stents to reduce clinical outcome and stent-related complications in CKD patients, a systematic review, meta-analysis and network meta-analysis 58
Efficacy versus safety: The dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease 52
Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events 48
Strategies for reducing door to balloon time in patients with acute myocardial infarction undergoing primary angioplasty: the Pavia experience 48
Comparison of Outcomes of Staged Complete Revascularization Versus Culprit Lesion–Only Revascularization for ST-Elevation Myocardial Infarction and Multivessel Coronary Artery Disease 41
The prognostic value of late gadolinium enhancement in hypertrophic cardiomyopathy: An updated meta-analysis 41
Lack of implementation of guidelines recommendations for coronary revascularization in stable patients with complex disease is associated with high rates of incomplete revascularization : Analysis from the Apache study. 40
Elevated serum uric acid affects myocardial reperfusion and infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention 39
DAPT Score to Stratify Ischemic and Bleeding Risk after Percutaneous Coronary Intervention: An Updated Systematic Review, Meta-Analysis, and Meta-Regression of 100,211 Patients 37
Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis 34
Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study 34
Comparison of antithrombotic strategies in patients with cryptogenic stroke and patent foramen ovale: an updated meta-analysis 33
APpropriAteness of percutaneous Coronary interventions in patients with ischaemic HEart disease in Italy: The APACHE pilot study 32
Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention: A network meta-analysis 32
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial 32
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A subgroup analysis of the ARISTOTLE trial 31
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial 31
Ticagrelor Alone or Conventional Dual Antiplatelet Therapy in Patients With Stable or Acute Coronary Syndromes 30
Clinical governance programme in patients with acute coronary syndrome: Design and methodology of a quality improvement initiative 30
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 29
Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial 29
Alirocumab and cardiovascular outcomes after acute coronary syndrome 29
Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management: AKI-MATRIX 28
Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease 28
Aspirin Desensitization in Patients with Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). 28
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial 28
PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY 28
Acute Cardiovascular Care 2019 27
Association of Troponin Levels with Mortality in Italian Patients Hospitalized with Coronavirus Disease 2019: Results of a Multicenter Study 27
Early Complete Revascularization in Hemodynamically Stable Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease 26
Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: A systematic review and meta-analysis 26
Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasivemanagement: Secondary analysis of a randomized clinical trial 26
Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study 26
Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients with ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial 26
Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY 26
Sotagliflozin in patients with diabetes and recent worsening heart failure 26
Oral aspirin or low dose of intravenous lysine acetylsalicylate in ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention 26
Parenteral antithrombotic therapy during primary percutaneous coronary intervention 25
Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions: Insights from the EmploYEd antithrombotic therapies in patients with acute coronary Syndromes HOspitalized in Italian cardiac care units Registry 25
Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management 25
Around the clock, around the world-reflections on 24 hours of acute cardiovascular care 25
Consistent Reduction in Periprocedural Myocardial Infarction with Cangrelor as Assessed by Multiple Definitions: Findings from CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) 24
Apixaban versus warfarin in patients with atrial fibrillation 24
Primum non nocere: An updated meta-analysis on aspirin use in primary prevention of cardiovascular disease in patients with diabetes 24
Acute myocardial infarction complicating ischemic stroke: is there room for cangrelor? 24
The future for the Acute Cardiovascular Care Congress we shall find together 24
Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure 24
Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets 24
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol 24
Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial 23
Antithrombotic Therapy in Patients With Acute Coronary Syndrome Complicated by Cardiogenic Shock or Out-Of-Hospital Cardiac Arrest: A Joint Position Paper From the European Society of Cardiology (ESC) Working Group on Thrombosis, in Association With the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI) 23
Meta-Analysis Comparing Potent Oral P2Y12 Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 23
Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): Randomised controlled trial 23
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis 23
Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study) 22
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data 22
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2 22
Myocarditis in a 16-year-old boy positive for SARS-CoV-2 22
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study 22
2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group 22
Reply: Digoxin Use in Atrial Fibrillation: Minimizing and Refining its Use When Still Needed 21
Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study 21
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment 21
Return towards normality in admissions for myocardial infarction after the lockdown removal for COVID-19 outbreak in Italy 21
The prognostic value of serial troponin measurements in patients admitted for COVID-19 21
Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome 20
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-st-segment elevation acute coronary syndrome (from the tracer trial) 20
Incidence of ventricular arrhythmias and 1-year predictors of mortality in patients treated with implantable cardioverter-defibrillator undergoing generator replacement 20
Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study 20
Short-and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: Insights from four validated bleeding scales in the CHAMPION trials 20
Composition, structure, and function of heart teams: A joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization 19
Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study 19
Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes 19
Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes 19
Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention: Results from CHAMPION PHOENIX 18
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes 18
Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting 17
Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study 17
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study 16
Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the augustus trial 16
Reduction of Hospitalizations for Myocardial Infarction in Italy in the COVID-19 Era 16
Cangrelor: Review of the Drug and the CHAMPION Programme (Including PHOENIX) 16
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: Insights from the CHAMPION percutaneous coronary intervention trial 15
A novel approach to systematically implement the universal definition of myocardial infarction: Insights from the CHAMPION PLATFORM trial 15
Practical considerations for cangrelor use in patients with acute coronary syndromes 15
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study 15
Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score 15
Cardiac troponin after percutaneous coronary intervention and 1-year mortality in Non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends 14
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial 14
Will PIONEER AF-PCI change my practice? 14
Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function 14
Sex-related differences in patients with coronavirus disease 2019: results of the Cardio-COVID-Italy multicentre study 13
Effect of platelet inhibition with Cangrelor during PCI on ischemic events 13
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y 12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: The INNOVATE-PCI trial 13
Thrombin receptor antagonists for the treatment of atherothrombosis: Therapeutic potential of vorapaxar and E-5555 13
Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest 13
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: The GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) 13
Bivalirudin or unfractionated heparin in acute coronary syndromes 13
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience 13
Totale 2470
Categoria #
all - tutte 8961
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8961

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201819 0000 00 00 01063
2018/201918 3080 01 40 1001
2019/2020240 274115 62 07 22214113
2020/2021186 32123 109 568 2217413
2021/2022589 203388 105 1235 26986337
2022/20231844 2281381888 114140 990 1019000
Totale 2922